For research use only. Not for therapeutic Use.
Evocalcet (KHK7580) is an orally active calcium sensing receptor (CaSR) agonist. Evocalcet inhibits the secretion of parathyroid hormone (PTH) from parathyroid gland cells. Evocalcet can be used for the research of hyperparathyroidism[1][2].
Evocalcet (0, 20 and 60 nM) dose-dependently increases [Ca2+]i with an EC50 value of 92.7 nM in hCaR-HEK293 cells[2].
Evocalcet shows no significant inhibitory effects on the specific activities of any (cytochrome P450) CYP isozymes[2].
Evocalcet (0.03 or 0.3 mg/kg; oral Administration, once) affects serum PTH and Ca levels[1].
Evocalcet (0.3 mg/kg; oral Administration, once daily, for 5 weeks) reduces the serum PTH and Ca levels and increases the serum IP (inorganic phosphorus) level[1].
| Catalog Number | I006742 |
| CAS Number | 870964-67-3 |
| Synonyms | 2-[4-[(3S)-3-[[(1R)-1-naphthalen-1-ylethyl]amino]pyrrolidin-1-yl]phenyl]acetic acid |
| Molecular Formula | C24H26N2O2 |
| Purity | ≥95% |
| InChI | InChI=1S/C24H26N2O2/c1-17(22-8-4-6-19-5-2-3-7-23(19)22)25-20-13-14-26(16-20)21-11-9-18(10-12-21)15-24(27)28/h2-12,17,20,25H,13-16H2,1H3,(H,27,28)/t17-,20+/m1/s1 |
| InChIKey | RZNUIYPHQFXBAN-XLIONFOSSA-N |
| SMILES | CC(C1=CC=CC2=CC=CC=C21)NC3CCN(C3)C4=CC=C(C=C4)CC(=O)O |
| Reference | [1]. Sakai M, et al. Evocalcet prevents ectopic calcification and parathyroid hyperplasia in rats with secondary hyperparathyroidism. PLoS One. 2020 Apr 28;15(4):e0232428. [2]. Kawata T, et al. A novel calcimimetic agent, evocalcet (MT-4580/KHK7580), suppresses the parathyroid cell function with little effect on the gastrointestinal tract or CYP isozymes in vivo and in vitro. PLoS One. 2018 Apr 3;13(4):e0195316. |
